Abl Bio, Inc.
Clinical trials sponsored by Abl Bio, Inc., explained in plain language.
-
New antibody drug takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called ABL103 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to check safety, find the right dose, and see if it sh…
Phase: PHASE1 • Sponsor: ABL Bio, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug (ABL103) combined with an existing immunotherapy (pembrolizumab) and sometimes a chemotherapy (taxane) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrin…
Phase: PHASE1, PHASE2 • Sponsor: ABL Bio, Inc. • Aim: Disease control
Last updated Jun 02, 2026 11:58 UTC